(Reuters) - AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall ...
CAPItello-290 Phase III trial of Truqap/paclitaxel combo (Il Sole 24 Ore Radiocor) - London, 18 Jun - Anglo-Swedish drug company AstraZeneca said that the CAPItello-290 Phase III trial for Truqap ...
(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the CAPItello-290 Phase III trial for Truqap (capivasertib) plus chemotherapy in patients with locally advanced ...
Breast cancer drug Truqap, manufacturer AstraZeneca, failed main goal in CAPItello-290 trial for metastatic triple-negative breast cancer. Triple-negative breast cancer (TNBC) is a type of breast ...
Collectively, mutations in PIK3CA, AKT1, and alterations in PTEN affect approximately 35% of patients with TNBC. The safety profile of Truqap plus paclitaxel was broadly consistent with the known ...
(Reuters) - AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall ...